This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
ArQule, Inc.
ArQule, Inc., a prominent biopharmaceutical company headquartered in the United States, is dedicated to advancing innovative therapies for cancer and other serious diseases. Founded in 1990, ArQule has established itself as a leader in the development of targeted therapies, particularly in the field of oncology. The company’s core offerings include a range of proprietary drug candidates that leverage its unique drug discovery platform, setting it apart in a competitive market. With a strong focus on precision medicine, ArQule has achieved significant milestones, including partnerships with major pharmaceutical firms and successful clinical trials. Its commitment to scientific excellence and patient-centric solutions has positioned ArQule as a notable player in the biopharmaceutical industry, driving advancements that aim to improve patient outcomes globally.
DitchCarbon Score
How does ArQule, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ArQule, Inc.'s score of 50 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
ArQule, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. However, the company is part of a corporate family that includes Merck & Co., Inc., from which it inherits climate commitments and initiatives. As a current subsidiary of Merck & Co., Inc., ArQule aligns with the sustainability goals set by its parent company. Merck has established science-based targets (SBTi) aimed at reducing greenhouse gas emissions across its operations. While specific reduction targets for ArQule are not detailed, the overarching initiatives from Merck include commitments to reduce emissions in line with global climate goals. ArQule's climate strategy is influenced by Merck's performance and initiatives, which encompass various frameworks such as the Carbon Disclosure Project (CDP) and the RE100 initiative. These commitments reflect a broader industry trend towards sustainability and responsible environmental stewardship. In summary, while ArQule, Inc. does not provide specific emissions data or reduction targets, it is actively engaged in climate commitments through its affiliation with Merck & Co., Inc., which sets a precedent for sustainability within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | |
|---|---|
| Scope 1 | - |
| Scope 2 | 245.3 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
ArQule, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
